

## **Amino acids levels related to glutamine supplementation for type 2 diabetes patients.**

**Asieh Mansour<sup>1,2</sup>, Saeed Hosseini<sup>3</sup>, Mostafa Qorbani<sup>4,5</sup>, Bagher Larijani<sup>6</sup>, Mohammad Reza Mohajeri-Tehrani<sup>3\*</sup>**

<sup>1</sup>Obesity and Eating Habits Research Center, Endocrinology and Metabolism Molecular -Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

<sup>2</sup>School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran

<sup>3</sup>Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

<sup>4</sup>Non-communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran

<sup>5</sup>Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Endocrinology and Metabolism Research Institute, Tehran University of Medical Sciences, Tehran, Iran

<sup>6</sup>Diabetes Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

### **Abstract**

**Aim:** Amino acids levels are changed upon glutamine administration, but the impact of glutamine administration on plasma amino acid levels in type 2 diabetes patients remains unclear.

**Methods:** A placebo controlled, randomized trial was performed with type 2 diabetic patients who consumed 2 supplements containing glutamine (10 g/3 times a day) or placebo (1 g/3 times a day) every day for 6 consecutive weeks. Blood samples were obtained just before initiation of study and again after the patients had received the study supplements.

**Results:** Dietary supplementation with glutamine didn't affect concentrations of plasma amino acid apart from for threonine. Plasma threonine concentration in intervention group was low at week 6 compared with placebo (glutamine group=111.19 ± 38.60 µmol/l, placebo group=135.30 ± 47.42 µmol/l; P=0.02).

**Conclusion:** In type 2 diabetes patients, oral glutamine supplementation resulted in a decreased level of threonine.

**Keywords:** Amino acids, Glutamine, Threonine, Type 2 diabetes.

*Accepted on June 08, 2018*

### **Introduction**

Glutamine as “conditionally essential” amino acid is the most abundant element in human blood and serves not only the role as regulator of acid-base homeostasis and in gluconeogenesis, but also plays roles as a “nitrogen shuttle” between various organs, involved in as an important oxidative fuel for rapidly proliferating cells including enterocytes, reticulocytes and immune cells. Also, glutamine has a signaling role in many processes including cell proliferation [1-3]. Dietary intake of glutamine has previously been demonstrated to be a strong stimulant of GLP-1 release leading to an effect associated with increased insulin circulation [4,5]. More recently, evidence available to determine whether oral glutamine is necessary or beneficial when consumed in patients with type 2 diabetes

[5,6]. Results of previous studies have indicated the absence of adverse effect of glutamine administration in adult human when consumed in 0.57-0.75 g.kg<sup>-1</sup> per day [7].

To date, it is unknown whether dietary glutamine can exert influence on aminoacidemia in diabetes patients. So that in a number of published studies either a short duration of glutamine administration was investigated in non-diabetic population or were done in animal models [8-11]. Also, little is known about its effects on plasma concentrations of amino acid in humans and animals. These concerns limit our confidence for oral administration of glutamine to type 2 diabetes and underscore the need for longer study. Here, in this article, we aimed to examine the influences of a glutamine-enriched diet on aminoacidemia that may raise the risk of

health problem through the alteration in amino acids levels in blood.

## Methods

A total of 66 adults with type 2 diabetes participated in this study, which was approved by Tehran University of Medical Sciences Ethics Committee registration number 197, and registered at IRCT, registration number IRCT201205279373N1. All tests were performed in the morning after an overnight fast. Blood samples were put in to EDTA tubes and centrifuged for 15 min at 2500 g. The plasma concentration of free amino acids were determined by HPLC. The inclusion criteria into the study were having a BMI (in kg/m<sup>2</sup>)<35, blood pressure<160/90 mmHg. Exclusion criteria for both groups were hepatic or renal disorder, malignancy, autoimmune diseases and history of drug abuse. In addition, patients who were using a restrictive diet or weight change>5 kg before the study were excluded. Moreover, patients with a history of prior corticosteroids use, hormones therapy or using antibiotic drugs, taking any medication known for weight loss, and treatment with anti-inflammatory medication were excluded from the study. Following baseline examination, all eligible participants were randomly assigned to one of two groups: 10 g/3 times a day of glutamine; or 1 g/3 times a day placebo in a double blind manner. All tests were repeated following a 6-week therapy. Pre to post differences were analyzed using a general linear model ANCOVA and baseline differences between two groups were analyzed using independent samples t-test. Data were analyzed using the Statistical Package for the Social Sciences version 18 (SPSS Inc., Chicago, IL). Significance level was taken as P<0.05.

## Results

53 males and females, 27 in the glutamine group and 26 in the placebo group who aged 51.5 ± 6.89 y; mean ± SD, and had diabetes (glutamine group=73.64 ± 14.72 months, placebo group=75.16 ± 54.62 months; mean ± SD, P=0.71), completed the trial and were included in the statistical analyses. Holecek published a review oPlasma amino acid profiles are shown in Table 1. No differences were observed between groups in terms of plasma concentration of free amino acid before the trial. After 6 weeks of supplementation with glutamine, there were no significant differences in amino acid levels, excepting threonine levels at week 6 (glutamine group=111.19 ± 38.60 μmol/l, placebo group=135.30 ± 47.42 μmol/l; P=0.02), which showed a significant decrease in glutamine group in comparison with placebo.

**Table 1.** Plasma amino acid concentration in baseline and after 6 weeks glutamine supplementation.

Amino acids	Glutamine (n=27) (μmol/l)	Placebo (n=26) (μmol/l)	P value
Aspartate			
Baseline	8.00 ± 3.16	8.91 ± 3.94	0.36

Week 6	6.54 ± 3.48	6.04 ± 2.52	0.61
Glutamic acid			
Baseline	99.38 ± 44.13	95.46 ± 35.20	0.72
Week 6	105.71 ± 52.24	116.94 ± 60.46	0.36
Asparagine			
Baseline	47.45 ± 15.12	49.89 ± 16.23	0.57
Week 6	40.47 ± 11.60	41.85 ± 12.04	0.86
Serine			
Baseline	123.35 ± 48.10	120.96 ± 33.95	0.83
Week 6	107.77 ± 38.67	110.86 ± 37.84	0.44
Histidine			
Baseline	108.98 ± 35.84	128.27 ± 60.09	0.16
Week 6	75.10 ± 19.84	75.37 ± 21.56	0.61
Glutamine			
Baseline	493.92 ± 154.00	536.76 ± 147.20	0.31
Week 6	498.52 ± 182.75	486.44 ± 151.66	0.49
Arginine			
Baseline	37.31 ± 14.38	43.72 ± 22.88	0.23
Week 6	36.12 ± 17.92	36.28 ± 19.32	0.62
Citrulline			
Baseline	21.82 ± 9.01	24.01 ± 12.26	0.46
Week 6	24.79 ± 13.77	26.53 ± 11.04	0.71
Glycine			
Baseline	269.64 ± 180.42	317.72 ± 128.68	0.27
Week 6	171.00 ± 80.14	215.52 ± 97.96	0.17
Threonine			
Baseline	143.64 ± 52.09	138.82 ± 39.92	0.71
Week 6	111.19 ± 38.60	135.30 ± 47.42	0.02*
Isoleucine			
Baseline	75.78 ± 21.21	76.42 ± 27.97	0.92
Week 6	84.66 ± 27.66	84.22 ± 27.02	0.94
Leucine			
Baseline	138.04 ± 35.19	141.61 ± 44.80	0.75
Week 6	153.23 ± 44.84	155.34 ± 45.41	0.88
Alanine			
Baseline	511.30 ± 163.94	562.88 ± 172.46	0.27
Week 6	422.99 ± 99.89	498.59 ± 142.95	0.19
Tyrosine			
Baseline	65.76 ± 27.73	68.33 ± 22.42	0.71

Week 6	69.77 ± 20.67	75.10 ± 20.94	0.39
Tryptophan			
Baseline	49.97 ± 14.79	56.69 ± 18.14	0.14
Week 6	64.61 ± 19.99	68.10 ± 17.72	0.61
Methionine			
Baseline	26.34 ± 7.76	27.10 ± 8.21	0.73
Week 6	27.57 ± 7.09	30.14 ± 7.02	0.2
Valine			
Baseline	241.23 ± 60.78	250.49 ± 77.28	0.63
Week 6	270.44 ± 83.25	277.27 ± 76.11	0.79
Phenylalanine			
Baseline	56.28 ± 12.33	61.20 ± 13.91	0.18
Week 6	63.74 ± 14.93	66.03 ± 16.42	0.63
Ornithine			
Baseline	99.66 ± 56.00	87.87 ± 47.86	0.41
Week 6	89.87 ± 41.65	111.96 ± 57.69	0.12
Lysine			
Baseline	174.67 ± 65.87	151.66 ± 63.63	0.2
Week 6	155.73 ± 65.49	178.66 ± 56.02	0.23

Values are mean ± SEM; ANCOVA P value for comparison between glutamine and placebo groups at the end of study. Independent samples t-test P value for comparison between glutamine and placebo groups at the baseline. \*Significant was taken as  $P < 0.05$ .

## Discussion

These results indicate that supplementary glutamine decreased serum concentrations of the threonine in type 2 diabetes patients. Threonine is a major component of intestinal mucin protein and there is evidence indicating that threonine plays an important role in many physiological and biochemical processes including modulating immune function, inhibition of apoptosis, stimulation of lymphocyte proliferation, and glycine synthesis [12,13]. Since threonine is involved in a number of important metabolic functions, therefore, a decrease in protein synthesis and severe metabolic alterations is partly caused by its reduction [14]. The mechanisms for glutamine-induced decrease in threonine concentration in plasma remain to be elucidated. In their rodent models, Moundras et al. showed that this decrease may be as a consequence of upregulation of serine (threonine) dehydratase by glutamine [15].

It has been established that glutamine supplementation raises and lowers the plasma levels of several amino acid levels (is not homogeneous) depends on various factors which are related to the choice of the form, doses and method (enteral or parenteral) on which it may be administered and likely to depend on many other different factors, including the nature of disease and its severity [16]. Our results are in agreement with Holecek who observed a significant reduction in threonine in

plasma following 3 months of an increased consumption of glutamine in male Wistar rats [1]. Similarly in male Sprague-Dawley rats, Jeevanandam et al. found a significant reduction in plasma levels of threonine following 4 d of supplementation with glutamine in intact rats [10]. They also observed a decrease in the plasma levels of this amino acid in the traumatized rats group; however, it did not reach statistical significance. The absence of any changes in plasma levels of several amino acids except threonine after long-term glutamine administration with each main meal seems to be in contrast with studies that assessed the plasma amino acid response to the ingestion of diet enriched with glutamine in rodents models and also in human [1,10,17,18].

Holecek published a review on the side effects of glutamine supplementation, in which he concluded that despite its noticeable alterations in aminoacidemia, the short-term use of glutamine can be safely consumed in large amount [16]. However, studies focused on the impact of glutamine on aminoacidemia among human are subject to limitations. Dechelotte et al. tested plasma levels of amino acid in healthy volunteers inserted nasojunal tube (enterally administered glutamine) over 1 or 2.5 h [9]. Svanberg et al. tested such effect in healthy volunteers by glutamine provision (intravenously) over 2.5 h in 5 males, and Rutten et al. investigated the amino acid levels from 8 chronic obstructive pulmonary disease patients 80 min after glutamine drink and then compared the results with those of 8 healthy individuals [19,20]. Moreover, a large proportion of these studies analyzing aminoacidemia after glutamine intake used only one arm with no comparison between different subgroups [9,17,18]. As well, another limitation to consider is the duration of studies which were short. Such limitation was resolved in this study by including an arm (placebo group) and increasing the duration of study time.

Evidence has been reported that of the oxidation rate of glutamate and the activity of glutamine synthesis were reduced in the diabetic retina. Elevated glutamate is thought to play a significant role in the pathogenesis of diabetic retinal neurodegeneration by overstimulation of its receptors [21]. In our study, we found no evidence of a significant increase in plasma glutamate levels due to glutamine supplementation.

## Conclusion

It is therefore suggested that the enhancement of glutamine intake contributes to the depletion of plasma threonine. Further research should be carried out for a better understanding of the physiological role of these findings.

## References

1. Holecek M. Adverse effects of chronic intake of glutamine-supplemented diet on amino acid concentrations and protein metabolism in rat: Effect of short-term starvation. *Eur J Clin Nutr Metab* 2011; 6: 190-196.

2. Rao R, Samak G. Role of glutamine in protection of intestinal epithelial tight junctions. *J Epithel Biol Pharmacol* 2012; 5: 47.
3. Zellner M, Gerner C, Eliassen MM. Glutamine starvation of monocytes inhibits the ubiquitin-proteasome proteolytic pathway. *Biochim et Biophys Acta* 2003; 1638: 138-148.
4. Reimann F, Williams L, da Silva Xavier G, Rutter GA, Gribble FM. Glutamine potently stimulates glucagon-like peptide-1 secretion from GLU Tag cells. *Diabetologia* 2004; 47: 1592-1601.
5. Greenfield JR, Farooqi IS, Keogh JM. Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects. *Am J Clin Nutr* 2009; 89: 106-113.
6. Samocha-Bonet D, Wong O, Synnott E-L. Glutamine reduces postprandial glycemia and augments the glucagon-like peptide-1 response in type 2 diabetes patients. *J Nutr* 2011; 141: 1233-1238.
7. Watford M. Glutamine metabolism and function in relation to proline synthesis and the safety of glutamine and proline supplementation. *J Nutr* 2008; 138: 2003-2007.
8. Ockenga J, Borchert K, Stüber E, Lochs H, Manns MP, Bischoff SC. Glutamine-enriched total parenteral nutrition in patients with inflammatory bowel disease. *Eur J Clin Nutr* 2005; 59: 1302-1309.
9. Dechelotte P, Darmaun D, Rongier M, Hecketsweiler B, Rigal O, Desjeux J-F. Absorption and metabolic effects of enterally administered glutamine in humans. *Am J Physiol Gastrointest Liver Physiol* 1991; 260: 677-682.
10. Jeevanandam M, Holaday NJ, Petersen SR. Altered brain and muscle amino-acid levels due to remote injury during glutamine supplementation. *Clin Nutr* 1995; 14: 365-372.
11. Holecek M, Skopec F, Skalská H, Šprongl L. Effect of alanyl-glutamine on leucine and protein metabolism in endotoxemic rats. *J Parenter Enteral Nutr* 2000; 24: 215-222.
12. Li P, Yin Y-L, Li D, Kim SW, Wu G. Amino acids and immune function. *Br J Nutr* 2007; 98: 237-252.
13. Wu G. Amino acids: metabolism, functions, and nutrition. *Amino Acids* 2009; 37: 1-17.
14. Di Pasquale MG. Amino acids and proteins for the athlete: The anabolic edge Boca Raton, FL. CRC Press 2007.
15. Moundras C, Rémésy C, Bercovici D, Demigné C. Effect of dietary supplementation with glutamic acid or glutamine on the splanchnic and muscle metabolism of glucogenic amino acids in the rat. *J Nutr Biochem* 1993; 4: 222-228.
16. Holecek M. Side effects of long-term glutamine supplementation. *J Parenter Enteral Nutr* 2012; 0148607112460682.
17. Melis GC, Boelens PG, van der Sijp JRM. The feeding route (enteral or parenteral) affects the plasma response of the dipeptide Ala-Gln and the amino acids glutamine, citrulline and arginine, with the administration of Ala-Gln in preoperative patients. *Br J Nutr* 2005; 94: 19-26.
18. Valencia E, Marin A, Hardy G. Impact of oral L-glutamine on glutathione, glutamine, and glutamate blood levels in volunteers. *Nutrition* 2002; 18: 367-370.
19. Svanberg E, Möller-Loswick, A-C, Matthews DE, Körner U, Lundholm K. The effect of glutamine on protein balance and amino acid flux across arm and leg tissues in healthy volunteers. *Clin Physiol* 2001; 21: 478-489.
20. Rutten EPA, Engelen MPKJ, Wouters EFM, Schols AMWJ, Deutz NEP. Metabolic effects of glutamine and glutamate ingestion in healthy subjects and in persons with chronic obstructive pulmonary disease. *Am J Clin Nutr* 2006; 83: 115-123.
21. Tombran-Tink J, Barnstable CJ, Gardner TW. Visual dysfunction in diabetes: The science of patient impairment and health care. Springer Science and Business Media 2011.

**\*Correspondence to**

Mohammad Reza Mohajeri-Tehrani  
Endocrinology and Metabolism Research Center  
Endocrinology and Metabolism Clinical Sciences Institute  
Tehran University of Medical Sciences  
Tehran  
Iran